Companies

See how salaries can vary from company to company

Commercial Pest Control Pest control in the commercial environment presents unique challenges. The presence of insect and rodent pests in a business is not only embarrassing, it: *Leads to the loss of current and potential customers *Lowers employee morale and productivity. *In high tech areas such as computer rooms or control panels, the presence of insect and rodent pests can lead to loss of data. *Equipment malfunction. *Structural damage due to fires. A business cannot afford to take chances when selecting a pest control service. The Commercial Division of Cook's Pest Control can: *Free yo... view company details

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi ... view company details

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an o... view company details

Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California. view company details

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. view company details

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. view company details

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood The... view company details

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-C... view company details

We believe the freshest, most consistent milk product ingredients lead to the best tasting end products. And we are the only supplier on the planet whose ultra-fresh milk products can transition from our milking parlors to final packaging within twenty-four hours. Our dedication to freshness results in better tasting, better performing dairy ingredients. Our IdaPro Milk Proteins and Milk Permeate add a new level of Freshness, Flavor, Functionality and Value to applications from yogurt and sports nutrition beverages to soups, sauces and bakery. view company details

IHS Markit is a global leader in information, analytics and solutions for the major industries and markets that drive economies worldwide. Our company partners with clients in business, finance and government to help them see the big picture with unrivaled insights that lead to well-informed, confident decisions. IHS Markit serves more than 50,000 key customers in over 140 countries, including 85 percent of the Fortune Global 500. Headquartered in London, IHS Markit (NYSE: INFO) is committed to sustainable, profitable growth. view company details

InfuCare Rx is a leading data driven nationwide specialty infusion therapy provider focused on treating patients with chronic conditions who require comprehensive clinical management services. Today, many chronic conditions require specialized infusion therapies to help patients lead a healthy and productive lifestyle. InfuCare Rx provides a consistent, coordinated infusion experience for patients in the convenience of their home or alternate care setting. Our dedicated team of pharmacists, nurses and other trained professionals strive to provide optimal patient outcomes through cost effective... view company details

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017.... view company details

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and liver diseases. Its lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase II clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. The company also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS; and ZGN-1345, an orally dosed MetAP2... view company details

LGK is a statewide movement to make Vermont the best place to raise a family and our mission is to ensure affordable access to high-quality child care for all Vermont families by 2025. We work with our partners throughout the state to build high-quality child care and we're calling for more public investment in child care so that it's affordable for families. Together, we will make historic change that will lead to opportunity for our children, families and Vermont's future. view company details

Life.Church is one church in multiple locations, meeting across the United States and globally at Church Online. Our mission is to lead people to become fully devoted followers of Christ. We are risk-taking, irrationally generous, spiritual contributors who bring our best, laugh hard, and honor God with integrity. Visit www.life.church/careers to learn more about the hiring process, take a look at our benefits, and see what it's like to work at Life.Church. view company details

The Los Angeles Homeless Services Authority (LAHSA) is a joint powers authority of the city and county of Los Angeles, created in 1993 to address the problem of homelessness in Los Angeles County. LAHSA is the lead agency in the HUD-funded Los Angeles Continuum of Care, and coordinates and manages over $300 million annually in federal, state, county, and city funds for programs providing shelter, housing, and services to people experiencing homelessness. Apply online for a job in homeless services: https://www.lahsa.org/jobs view company details

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ss-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ss-selective small molecule that is in preclinical trial... view company details

Outlook Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its lead clinical program is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in Phase I clinical trial for the treatment of wet age related macular degeneration. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jer... view company details

Welcome to the LinkedIn page of the Oklahoma Department of Human Services! Follow this page for information about career opportunities and news about DHS. Our mission: We improve the quality of life of vulnerable Oklahomans by increasing people's ability to lead safer, healthier, more independent and productive lives. Our vision: DHS provides help and offers hope to vulnerable Oklahomans through stronger practices, involved communities and a caring and engaged workforce. See our current career opportunities at the following link: https://www.jobapscloud.com/OK/?Keyword=&Loc=&DeptNumber=830000&... view company details

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a re... view company details